{"brief_title": "Study of Karenitecin (BNP1350) to Treat Malignant Melanoma", "brief_summary": "The purpose of this study is to evaluate the safety and efficacy of Karenitecin (BNP1350) as a treatment for Malignant Melanoma.", "condition": ["Melanoma", "Neoplasm"], "intervention_type": ["Drug"], "intervention_name": ["Karenitecin (BNP1350)"], "description": ["Karenitecn (1.0 mg/m2) administered as a single daily 60-minute intravenous infusion for 5 consecutive days repeated every 21 days (1 treatment cycle). Patients who respond (CR< PR, SD) can continue treatment for 6 cycles, unless unacceptable toxicity develops. Treatment will be discontinued if progressive disease or unacceptable toxicity develops."], "arm_group_label": ["1"], "criteria": "- Confirmed diagnosis of malignant melanoma - Measurable disease - Granulocytes \u22651,500/\u00b5l, Platelets \u2265100,000/\u00b5l, Creatinine \u2264ULN, Bilirubin \u22641.5 mg/dl, AST \u22642.5 x ULN - No prior treatment with other camptothecin drug. - \u2265 21 days since completion of prior chemotherapy, \u22656 weeks since prior Mitomycin-C - ECOG Performance Status 0-1 - Negative pregnancy test for female patients", "gender": "All", "minimum_age": "18 Years", "maximum_age": "N/A", "healthy_volunteers": "No", "mesh_term": ["Melanoma", "Camptothecin"], "id": "NCT00062491"}